The Genetics of Inflammatory Bowel Disease
Saved in:
| Title: | The Genetics of Inflammatory Bowel Disease |
|---|---|
| Authors: | El Hadad, Jasmina, Schreiner, Philipp, Vavricka, Stephan R, Greuter, Thomas |
| Contributors: | University of Zurich, Greuter, Thomas |
| Source: | Mol Diagn Ther Molecular diagnosis & therapy, vol. 28, no. 1, pp. 27-35 |
| Publisher Information: | Springer Science and Business Media LLC, 2023. |
| Publication Year: | 2023 |
| Subject Terms: | 610 Medicine & health, Humans, Genome-Wide Association Study, Inflammatory Bowel Diseases/diagnosis, Inflammatory Bowel Diseases/genetics, Colitis, Ulcerative/drug therapy, Colitis, Ulcerative/genetics, Colitis, Ulcerative/diagnosis, Crohn Disease/diagnosis, Crohn Disease/drug therapy, Crohn Disease/genetics, Azathioprine/therapeutic use, Review Article, Inflammatory Bowel Diseases, 3. Good health, 10219 Clinic for Gastroenterology and Hepatology, 3004 Pharmacology, 1311 Genetics, Crohn Disease, 1313 Molecular Medicine, Azathioprine, Colitis, Ulcerative |
| Description: | The genetic background of inflammatory bowel disease, both Crohn's disease and ulcerative colitis, has been known for more than 2 decades. In the last 20 years, genome-wide association studies have dramatically increased our knowledge on the genetics of inflammatory bowel disease with more than 200 risk genes having been identified. Paralleling this increasing knowledge, the armamentarium of inflammatory bowel disease medications has been growing constantly. With more available therapeutic options, treatment decisions become more complex, with still many patients experiencing a debilitating disease course and a loss of response to treatment over time. With a better understanding of the disease, more effective personalized treatment strategies are looming on the horizon. Genotyping has long been considered a strategy for treatment decisions, such as the detection of thiopurine S-methyltransferase and nudix hydrolase 15 polymorphisms before the initiation of azathioprine. However, although many risk genes have been identified in inflammatory bowel disease, a substantial impact of genetic risk assessment on therapeutic strategies and disease outcome is still missing. In this review, we discuss the genetic background of inflammatory bowel disease, with a particular focus on the latest advances in the field and their potential impact on management decisions. |
| Document Type: | Article Other literature type |
| File Description: | application/pdf; ZORA257279.pdf - application/pdf |
| Language: | English |
| ISSN: | 1179-2000 1177-1062 |
| DOI: | 10.1007/s40291-023-00678-7 |
| DOI: | 10.5167/uzh-257279 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/37847439 http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_CE26F5D1F4493 https://serval.unil.ch/notice/serval:BIB_CE26F5D1F449 https://serval.unil.ch/resource/serval:BIB_CE26F5D1F449.P001/REF.pdf |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) . |
| Accession Number: | edsair.doi.dedup.....c41bad42db9dc2b3ef10d2e05b1f6b83 |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | The genetic background of inflammatory bowel disease, both Crohn's disease and ulcerative colitis, has been known for more than 2 decades. In the last 20 years, genome-wide association studies have dramatically increased our knowledge on the genetics of inflammatory bowel disease with more than 200 risk genes having been identified. Paralleling this increasing knowledge, the armamentarium of inflammatory bowel disease medications has been growing constantly. With more available therapeutic options, treatment decisions become more complex, with still many patients experiencing a debilitating disease course and a loss of response to treatment over time. With a better understanding of the disease, more effective personalized treatment strategies are looming on the horizon. Genotyping has long been considered a strategy for treatment decisions, such as the detection of thiopurine S-methyltransferase and nudix hydrolase 15 polymorphisms before the initiation of azathioprine. However, although many risk genes have been identified in inflammatory bowel disease, a substantial impact of genetic risk assessment on therapeutic strategies and disease outcome is still missing. In this review, we discuss the genetic background of inflammatory bowel disease, with a particular focus on the latest advances in the field and their potential impact on management decisions. |
|---|---|
| ISSN: | 11792000 11771062 |
| DOI: | 10.1007/s40291-023-00678-7 |